62.21
-2.19(-3.40%)
Currency In USD
| Previous Close | 64.4 |
| Open | 63.77 |
| Day High | 63.85 |
| Day Low | 61.43 |
| 52-Week High | 105 |
| 52-Week Low | 29.18 |
| Volume | 73,546.24 |
| Average Volume | 182,306 |
| Market Cap | 416.75M |
| PE | -32.23 |
| EPS | -1.93 |
| Moving Average 50 Days | 57.61 |
| Moving Average 200 Days | 64.8 |
| Change | -2.19 |
Monopar Expands Leadership Team with Appointment of Seasoned Biopharma Executive Susan Rodriguez as Chief Commercial and Strategy Officer
GlobeNewswire Inc.
Mar 02, 2026 1:00 PM GMT
WILMETTE, Ill., March 02, 2026 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR) (“Monopar” or the “Company”), a clinical‐stage biopharmaceutical company developing innovative treatments for patients with unmet medical needs, today annou
Monopar Therapeutics Reports Third Quarter 2025 Financial Results and Recent Developments
GlobeNewswire Inc.
Nov 13, 2025 1:00 PM GMT
WILMETTE, Ill., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical‐stage biopharmaceutical company developing innovative treatments for patients with unmet medical needs, today announ
Monopar Presents New Data and Analyses on Rapidly Improved Copper Balance in Wilson Disease Patients on Tiomolybdate Choline at AASLD - The Liver Meeting® 2025
GlobeNewswire Inc.
Nov 09, 2025 2:00 PM GMT
WILMETTE, Ill., Nov. 09, 2025 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical-stage biopharmaceutical company developing innovative treatments for patients with unmet medical needs, is presentin